I don’t disagree. I’ve been part of deals on the buying and selling sides, but much larger in nature. Going to be interesting to see how this plays out. If Elite gets Vyvanse approval we are blazing our own trail from a multiple standpoint. I can’t find an equal competitor with low debt, growth mode, profitable and in generic pharma space. If we don’t already, we will soon have a target on our back.
Market Data 
Markets 
AI
